glp-1 drugs muscle loss and Loss: Semaglutide, Tirzepatide & Lean Mass Losing weight shouldn't mean losing
Description
On average, patients treated with exenatide lost 5.4 kg more weight compared to those treated with biphasic insulin aspart [58]
In 2024, the FDA approved Zepbound as the first GLP-1 medication specifically indicated to treat obstructive sleep apnea (OSA) in adults with obesity
Proponents claim these patches can suppress appetite, slow gastric emptying, and improve insulin secretioneffects associated with legitimate GLP-1 receptor agonists
Evidence in Tobacco Use Disorder In one RCT examining GLP-1 RAs in tobacco use disorder, semaglutide treatment reduced daily cigarette smoking
Some drug classes carry a higher risk due to their absorption characteristics or therapeutic importance
Recuperato da: Li J, Cao J, Wei J, Geng W, Li J-R, Cao J, et al
